We are live on ! Find out more
DM

Deerfield Management Portfolio holdings

AUM $8.48B
1-Year Est. Return 99.04%
This Fund
S&P 500
This Quarter Est. Return
+16.43%
1 Year Est. Return
+99.04%
3 Year Est. Return
+273.78%
5 Year Est. Return
+280.99%
10 Year Est. Return
+2,168.14%
AUM
$4.68B
AUM Growth
+$199M
Cap. Flow
-$1.42B
Cap. Flow %
-30.22%
Top 10 Hldgs %
50.13%
Holding
119
New
17
Increased
19
Reduced
10
Closed
18

Top Buys

Rank Stock Value
1
ICPT
Intercept Pharmaceuticals, Inc.
ICPT
+$29M
2
RVNC
Revance Therapeutics, Inc.
RVNC
+$27.1M
3
APLS
Apellis Pharmaceuticals
APLS
+$27M
4
AMED
Amedisys
AMED
+$25.5M
5
RVMD icon
Revolution Medicines
RVMD
+$22.6M

Top Sells

Rank Stock Value
1
NBIX icon
Neurocrine Biosciences
NBIX
+$52.3M
2
MIRM icon
Mirum Pharmaceuticals
MIRM
+$48.8M
3
ITCI
Intra-Cellular Therapies Inc.
ITCI
+$39.7M
4
ISEE
IVERIC bio, Inc. Common Stock
ISEE
+$36.6M
5
CPRX
Catalyst Pharmaceutical
CPRX
+$31.1M

Sector Composition

Rank Sector Weight
1 Healthcare 68.03%
2 Financials 0.35%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
NUVL
1
DELISTED
Nuvalent
NUVL
$843M 18%
19,991,024
– –
VTRS icon
2
Viatris
VTRS
$20.1B
$177M 3.77%
17,703,484
+767,487
+5% +$7.33M
AMED
3
DELISTED
Amedisys
AMED
$164M 3.5%
1,794,000
+310,821
+21% +$25.5M
AHCO icon
4
AdaptHealth
AHCO
$1.49B
$135M 2.88%
11,094,914
+500,000
+5% +$5.57M
NBIX icon
5
Neurocrine Biosciences
NBIX
$17.2B
$114M 2.44%
1,209,714
-535,000
-31% -$52.3M
CPRX
6
DELISTED
Catalyst Pharmaceutical
CPRX
$110M 2.35%
8,192,000
-2,163,099
-21% -$31.1M
DCPH
7
DELISTED
Deciphera Pharmaceuticals, Inc. Common Stock
DCPH
$94.4M 2.02%
6,707,026
+1,488,388
+29% +$21.3M
CNC icon
8
Centene
CNC
$32.8B
$91M 1.94%
1,349,000
+274,000
+25% +$18.3M
ACH
9
Accendra Health
ACH
$266M
$90.3M 1.93%
4,745,000
+877,545
+23% +$15.7M
MRUS
10
DELISTED
Merus
MRUS
$79.8M 1.7%
3,031,938
+651,500
+27% +$14.3M
SPRY icon
11
ARS Pharmaceuticals
SPRY
$695M
$74.2M 1.58%
11,077,927
– –
HLVX
12
DELISTED
HilleVax
HLVX
$57.2M 1.22%
3,329,231
+495,541
+17% +$7.68M
EHAB
13
DELISTED
Enhabit
EHAB
$55.3M 1.18%
4,809,803
+1,411,057
+42% +$17.6M
BKD icon
14
Brookdale Senior Living
BKD
$3.58B
$53.5M 1.14%
12,679,651
-3,726,396
-23% -$14.4M
IDYA icon
15
IDEAYA Biosciences
IDYA
$3.47B
$53.3M 1.14%
2,268,628
+525,000
+30% +$10.8M
LRMR icon
16
Larimar Therapeutics
LRMR
$384M
$53M 1.13%
16,941,357
– –
CMAX
17
DELISTED
CareMax, Inc. Class A Common Stock
CMAX
$49.3M 1.05%
528,703
– –
RVMD icon
18
Revolution Medicines
RVMD
$39.6B
$46.9M 1%
1,751,496
+921,759
+111% +$22.6M
GH icon
19
Guardant Health
GH
$20.7B
$44.9M 0.96%
1,253,999
+475,000
+61% +$13.6M
SWTX
20
DELISTED
SpringWorks Therapeutics
SWTX
$41.4M 0.88%
1,579,349
– –
COGT icon
21
Cogent Biosciences
COGT
$6.68B
$39.9M 0.85%
3,366,345
+400,000
+13% +$4.59M
SILK
22
DELISTED
Silk Road Medical, Inc. Common Stock
SILK
$36.8M 0.79%
1,132,229
-593,411
-34% -$21.7M
KURA icon
23
Kura Oncology
KURA
$964M
$34.3M 0.73%
3,238,000
+855,000
+36% +$10.1M
EWTX icon
24
Edgewise Therapeutics
EWTX
$4.28B
$30.5M 0.65%
3,933,137
– –
CABA icon
25
Cabaletta Bio
CABA
$461M
$30.2M 0.65%
2,340,118
+1,875,866
+404% +$20.4M
1
2 3 4 5

Similar funds

FT
Fiduciary Trust Boston, Massachusetts $8.46B AUM 21.38% 1-Year Est. Return
GRQ
Gardner Russo & Quinn Lancaster, Pennsylvania $8.5B AUM 9.79% 1-Year Est. Return
AV
ASR Vermogensbeheer Utrecht, Netherlands $8.5B AUM 25.14% 1-Year Est. Return
PCM
Penserra Capital Management Orinda, California $8.52B AUM 37.76% 1-Year Est. Return
VA
Valmark Advisers Akron, Ohio $8.42B AUM 14.36% 1-Year Est. Return
QC
Quadrature Capital London, United Kingdom $8.4B AUM 63.34% 1-Year Est. Return
IC
Icahn Carl Sunny Isles Beach, Florida $8.55B AUM 29.29% 1-Year Est. Return
NW
NewEdge Wealth Pittsburgh, Pennsylvania $8.39B AUM 24.47% 1-Year Est. Return

Deerfield Management's Q2 2023 Portfolio in Review

As of Q2 2023, Deerfield Management held 119 positions worth $4.68B, up 4.4% from $4.49B the previous quarter. Its ten largest holdings account for 50% of the portfolio.

Deerfield Management withdrew a net $1.42B in Q2 2023, closing 18 positions and reducing 10 holdings. Its most notable exit was Mirum Pharmaceuticals, an estimated $48.8M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 68% of assets, up from 63% a quarter earlier, followed by Financials.

Against the trend, Deerfield Management opened a new position in Intercept Pharmaceuticals, Inc. worth $23M.

  • Deerfield Management's largest Q2 2023 buy was Intercept Pharmaceuticals, Inc.: 2,077,893 shares worth $23M.
  • Deerfield Management added most to Amedisys in Q2 2023, an estimated $25.5M increase.
  • Deerfield Management's biggest Q2 2023 reduction was Neurocrine Biosciences, cutting an estimated $52.3M.
  • Deerfield Management fully exited Mirum Pharmaceuticals in Q2 2023, selling an estimated $48.8M.
  • Deerfield Management's ten largest holdings make up 50% of its $4.68B portfolio in Q2 2023.
  • Deerfield Management opened 17 new positions and closed 18 in Q2 2023.
  • Deerfield Management's portfolio value rose 4.4% quarter-over-quarter to $4.68B.

Based on Deerfield Management's 13F filing for Q2 2023, filed 14 Aug 2023.